43 results about "Parenteral solutions" patented technology

Packaging materials and containers may be treated with sterilization dosages internally and externally using monochromatic, continuous wave, high-intensity, incoherent light in single and/or multiple light source configurations. The treatment systems and methods preserve physical and performance properties of the packaging/container while achieving a desired level of sterilization. The sterilized materials may be adapted for extended shelf life (ESL) products. The disclosed treatment systems and methods may also be used for sterilization of food and beverage products (either prepackaged or post packaged), medicines, pharmaceuticals, vitamins, infusion products, clinical and/or non-clinical solutions and systems, enteral and/or parenteral solutions and systems, and the like.

The invention discloses the novel combined coenzyme Q10 parenteral solution, mainly containing the coenzyme Q10 as active component, polyethylene glycol 15-hydroxyl stearate as solubilizing agent and water for injection as solvent. One or more solvents of cosolvent, acidity regulator, osmoregulator and stabilizing agents can be also added. Low hemolyzation, extreme low histamine release and higher physiological tolerance of a novel solubilizing agent Solutol HS 15 adopted by the parenteral solution remarkably improves clinical medication security and the compliance of a patient; and the parenteral solution has the advantages of good stability, longer period of validity, higher medication convenience for a clinician, better storage and stable transportation, higher security for the clinical medication and better compliance of the patient. The parenteral solution also has the advantages of simple preparation technology, simple and convenient quality control and lower production cost, thereby being beneficial to industrialization production.

The invention provides a method for preparing high-purity beta-Elemene from natural plants containing beta-Elemene such as curcuma zedoary (root tubers or stem tubers of the curcuma zedoary), Cymbopogon citratus (fresh leaves of the Cymbopogon citrates), Solidago virgaurea (roots, stems, leaves, flowers and seeds of the Solidago virgaurea) and the like so as to improve production efficiency from the initial raw materials to the high-purity beta-Elemene and reduce production cost. Compared with the prior art, the method is mainly characterized in that: the roots, stems, leaves, flowers and seeds of the natural plants are taken as raw materials, and volatile oil of specific parts of the natural plants is prepared by methods for extracting different volatile oil, and then is rectified by a rectification method to prepare high-content beta-Elemene; then impurity components are removed by an ethanol extraction method and a silver nitrate complexing extraction method; finally the beta-Elemene with the content between 95.0 and 99.9 percent is prepared by distillation under reduced pressure; and the beta-Elemene not only can be prepared into oral administrative preparations such as emulsion oral liquid, capsules and the like, but also can be prepared into parenteral administrative preparations such as emulsion parenteral solution, injection, cutaneous permeable agents, lung spray preparations, suppositories and the like. The method has novel design of experimental methods, simple instruments and equipment, concise operation steps and obviously shortened operation time, improves production efficiency and is suitable for industrial production.

Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D₅W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.

The invention relates to a composition containing glucosamine. The active ingredients of the composition are glucosamine or pharmaceutically acceptable salt thereof and lidocaine or pharmaceutically acceptable salt thereof, and the composition provided by the invention can be prepared into an injection, preferably a parenteral solution, more preferably a small-volume injection. The parenteral solution further comprises an antioxidant, a pH regulator and an alkaline solvent. The composition containing glucosamine provided by the invention can be used for overcoming the defects that freeze-drying preparation of glucosamine is long in freeze-drying time, high in energy consumption and not beneficial to production in the prior art and free-dying preparations in the same batch are different in the shape and solubility. Control on the stability of the parenteral solution and related substances is realized, and the side effect caused by degradation products is reduced, so that the safety and stability requirements of the parenteral solution are met. Therefore, the glucosamine parenteral solution provided by the invention can meet industrial production and can be safely and reliably applied to the field of medicine.

The invention relates to a method for preparing ceftiofur hydrochloride parenteral solution; the hydrochloride parenteral solution has the characteristics of even distribution and clear and transparent solution. The method comprises the following steps: (1) adding propylene glycol and ceftiofur hydrochloride with a volume equal to 60-70% of the total volume of ceftiofur hydrochloride parenteral solution to be prepared in a thick mixing tank; adding 2-10g ceftiofur hydrochloride for every 100ml of total volume of the ceftiofur hydrochloride parenteral solution; heating to 40-50 DEG C and stirring for rapid dissolving; (2) adding propylene glycol to reach the total volume of the ceftiofur hydrochloride parenteral solution to be prepared and cooling to 20-30 DEG C; (3) adding active carbon, stirring for 15-20 minutes and filtering; and (4) filling and sealing, sterilizing, light check and packing. The invention solves the problems of difficult and uneven injection of the ceftiofur hydrochloride parenteral solution of the existing technology and makes up the defects of easy-layer and inconvenient use of the ceftiofur hydrochloride suspension injection of the existing technology.

A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water.

An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol.

An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component.

A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and/or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

The invention discloses an acehytisine freeze-drying emulsion and a reparation method thereof. The acehytisine freeze-drying emulsion uses the acehytisine as the active component, comprises oil for injection, emulsifier, additive and freeze-drying protective agent generally used in pharmacy and is dispersed into the emulsifier combination solution having a grain diameter ranging from 300 to 400nm after being added with water for injection. Compared with the acehytisine hydrochloride parenteral solution, the invention can realize 1.36 times of AUC and 1.59 times of MRT with half dosage and has equivalent pesticide effect for resisting arrhythmia.

The invention relates to a Chinese traditional compound medicine and the preparative way of it, which is used to treat myocardial ischemia and improve the microcirculation. The medicine is made up with American ginseng and ophiopogonis and the main ingredients are American ginseng diol group saponin, para-panaxsaponin F11, ophiopogonis Steroid saponin and ophiopogonone, of which American ginseng diol group saponin can't be less than 14.848g, while the American ginseng three groups saponin can't be less than 8.016g. The medicine can be made into different dosage forms such as parenteral solution, high-capacity parenteral solution, freeze-drying powder ampul and so on. The administration route is through intravenous injection.

The invention discloses nelarabine parenteral solution and a method for preparing the same. In the process for preparing the parenteral solution, temperature is kept at 50 to 90 DEG C at which the yield of the prepared nelarabine parenteral solution is greatly improved, which provides a good illustration for the influence of the temperature on the stability of the solution of basic medicament andpharmaceutical adjuvant in the process for preparing the nelarabine parenteral solution, and the nelarabine parenteral solution prepared at the temperature is of great scientific significance.

The invention relates to an injector core bar component and an injector employed by the component. The core bar component comprises a sealing plug, a sealing plug base, a spring, a push-pull rod (a tail end of the push-pull rod is arranged with a small sealing plug) and an elastic bayonet lock. Under an interaction of the spring and the elastic bayonet lock, the sealing plug base can be steadily combined with the push-pull rod through the compression and bounce of the spring, press and bounce of the elastic bayonet lock and insertion and extraction of the small sealing plug. An effective automatic control on absorption and effluence of parenteral solution can be realized. In the light of an injector nozzle plug (cover), the injector can not be used secondly. The invention not only can automatically control reusage of the injector, but also can provide safety and reliability, rational design, simple structure, convenient operation and low cost, and the invention can be widely popularized.